Last reviewed · How we verify
Placebo matching Niraparib — Competitive Intelligence Brief
phase 3
PARP inhibitor (reference: niraparib)
PARP1/PARP2 (reference target)
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo matching Niraparib (Placebo matching Niraparib) — Tesaro, Inc.. This is a placebo control arm matching the active drug niraparib, a PARP inhibitor that blocks poly(ADP-ribose) polymerase enzymes to prevent DNA repair in cancer cells.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo matching Niraparib TARGET | Placebo matching Niraparib | Tesaro, Inc. | phase 3 | PARP inhibitor (reference: niraparib) | PARP1/PARP2 (reference target) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (PARP inhibitor (reference: niraparib) class)
- Tesaro, Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo matching Niraparib CI watch — RSS
- Placebo matching Niraparib CI watch — Atom
- Placebo matching Niraparib CI watch — JSON
- Placebo matching Niraparib alone — RSS
- Whole PARP inhibitor (reference: niraparib) class — RSS
Cite this brief
Drug Landscape (2026). Placebo matching Niraparib — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-matching-niraparib. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing